Phibro Animal Health (PAHC) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY26 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
February 4, 2026 4:25 PM ESTTEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq: PAHC) (Phibro or the Company) today announced financial results for its second quarter ended December 31, 2025, and its updated financial guidance for the year ending June 30, 2026.
Highlights for the three months ended December 31, 2025 (compared to the three months ended December 31, 2024):
Net sales of $373.9 million, an increase of $64.6 million, or 21% Net income of $27.5 million, an increase of $24.3 million Diluted earnings per share of $0.67, an increase of $0.59 Adjusted EBITDA of $68.1 million, an increase of $19.9 million, or 41% Adjusted... More